Corona-Lau C, Muñoz L, Wolpert E, Aguilar LM, Dehesa M, Gutiérrez C, Kershenobich D

Language: English
References: 38
Page: 104-108
PDF size: 176.49 Kb.

ABSTRACT

Background: A significant number of patients infected with hepatitis C virus remain unaware of their infection, as this is a silent disease for many years. Patients are frequently detected at advance stages of the disease. Objective: To identify the prevalence and viremic stage of hepatitis C among a general population cohort. Methods: Anti-hepatitis C virus detection and viral RNA were offered without cost to individuals who voluntarily considered it relevant to be examined, as part of the World Hepatitis Day annually from 2007-2014. Results: A total of 32,945 individuals were analyzed; 57% were female and 43% male. Of them, 75.7% were between 21-50 years old. In 59%, the sample was obtained at their work place and in 41% at the facilities of 12 private laboratories. Anti-hepatitis C virus was positive in 194 patients (0.58%), of which 129 (66%) were confirmed positive by polymerase chain reaction. The overall prevalence of viremic cases in the sample was 0.39%. Conclusions: Adequate estimation of the prevalence of anti-hepatitis C virus and viremic population, not only among high-risk groups but also in the general population, is central to the allocation of resources in an effort to reduce the consequences of the disease.

REFERENCES

1. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Center for Disease Control and Prevention. MMWR Recomm Rep. 2003; 52:1-13.

2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335-74.

3. Gullett JC, Nolte FS. Quantitative nucleic acid amplification methods for viral infections. Clin Chem. 2015;61:72-8.

4. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.

5. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331-8.

6. Ward JW. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013;21:15-9.

7. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45-57.

8. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm J Viral Hepat. 2014;21(Suppl 1):34-59.

9. Gane E, Kershenobich D, Seguin-Devaux C, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden J Viral Hepat. 2015;22(Suppl 1):46-73.

10. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945- 1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:817-22.

11. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int. 2011;31:18-29.

12. Selvarajah S, Busch MP. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther. 2012;17: 1423-9.

13. Alter HJ, Houghton M. Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat Med. 2000;6:1082-6.

14. Arain A, Robaeys G, Stöver H. Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis. 2014; 14(Suppl 6):S17.

15. Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health. 2014;104:816-21.

16. Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014;21:616-23.

17. Lee M-H, Yang H-I, Yuan Y, L’Italien G, Chen C-J. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270-80.

18. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30-60.

19. Loomba R, Rivera MM, McBurney R, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther. 2011;33:559-65.

20. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-31.

21. Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology. 2015;61:783-9.

22. Kupek E1, Petry A. Changes in the prevalence, incidence and residual risk for HIV and hepatitis C virus in Southern Brazilian blood donors since the implementation of NAT screening. Rev Soc Bras Med Trop. 2014;47:418-25.

23. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot- Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58:593-608.

24. Linas BP, Hu H, Barter DM, Horberg M, Hepatitis C screening trends in a large integrated health system. Am J Med. 2014;127: 398-405.

25. Talaat N, Yapali S, Fontana RJ, Conjeevaram HS, Lok AS. Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. J Viral Hepat. 2015; 22:481-8.

26. Oliveira AC, Bortotti AC, Nunes NN, El Bacha IA, Parise ER. Association between age at diagnosis and degree of liver injury in hepatitis C. Braz J Infect Dis. 2014;18:507-11.

27. Wang L, Xing J, Chen F, et al. Spatial analysis on hepatitis C virus infection in Mainland China: From 2005 to 2011. PLoS One. 2014;9:e110861.

28. Schanzer DL, Paquette D, Lix LM. Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis. CMAJ Open. 2014;2:E139-44.

29. Oliveira AC, Bortotti AC, Nunes NN, El Bacha IA, Parise ER. Association between age at diagnosis and degree of liver injury in hepatitis C. Braz J Infect Dis. 2014;18:507-11.

30. Valdespino JL, Conde-Gonzalez CJ, Olaiz-Fernández G, Palma O, Kershenobich D, Sepulveda J. Seroprevalence of hepatitis C in adults in Mexico: an emerging public health problem? Salud Pública Mex. 2007;49(Suppl 3):S395-403.

31. Cruz-Ruiz MA, López-Díaz F, González-Ibarra FP, Lara-Ortega C, Muñoz-Ledo Guzman AL, Patiño-Lopez GA. Prevalence of antibodies for the hepatitis C virus in the low land (bajio) region of Mexico. Arch Med Res. 2013;44:390-3.

32. Campollo O, Roman S, Panduro A, et al. Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. Drug Alcohol Depend. 2012;123:269-72.

33. Romero-Figueroa S, Ceballos-Salgado E, Santillan-Arreygue L, et al. Risk factors associated with hepatitis C virus infection in an urban population of the state of Mexico. Arch Virol. 2012;157: 329-32.

34. López-Colombo A, Meléndez-Mena D, Sedeño-Monge V, et al. Hepatitis C virus infection in patients and family members attending two primary care clinics in Puebla, Mexico. Ann Hepatol. 2014;13:746-52.

35. Medina-Mora ME, Borges G, Fleiz C, et al. Prevalence and correlates of drug use disorders in Mexico. Rev Panam Salud Publica. 2006;19:265-76.

36. Del Pino N, Oubiña JR, Rodríguez-Frías F, et al. Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina. World J Gastroenterol. 2013;19:5813-27.

37. Bruggmann P, Berg T, Øvrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;(Suppl 1):5-33.

38. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60:691-8.